When incorporated into two TCR-like CARs, (HLA)-A2/GPC3- and HLA-A2/WT1-specific nanobodies selectively recognize and lyse MHC/peptide complex-expressing tumor cells both in vivo and in vitro. Here, HLA-C is linked to neoplasm.